A-PREDICT: A phase II study of axitinib in patients with metastatic renal cell cancer unsuitable for nephrectomy (CRUKE/11/061).
Rosalie A. Fisher
No relevant relationships to disclose
Andrew Rowan
No relevant relationships to disclose
Mark Stares
No relevant relationships to disclose
Mark F Webster-Smith
No relevant relationships to disclose
Rebecca Lewis
No relevant relationships to disclose
Lucy S Kilburn
No relevant relationships to disclose
David Nicol
No relevant relationships to disclose
Grant Stewart
No relevant relationships to disclose
Agnieszka Michael
Honoraria - Pfizer
Naveen Vasudev
No relevant relationships to disclose
Steve Hazell
No relevant relationships to disclose
Samra Turaljic
No relevant relationships to disclose
Lisa M. Pickering
Consultant or Advisory Role - Pfizer
Martin Eric Gore
No relevant relationships to disclose
Claire Snowdon
No relevant relationships to disclose
Judith M. Bliss
Honoraria - Pfizer
Research Funding - Pfizer
Charles Swanton
Research Funding - Pfizer
James M. G. Larkin
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Pfizer
Research Funding - Novartis; Pfizer